BATON ROUGE, La., Oct. 12, 2017 -- In keeping with its growing efforts to tackle the most serious chronic illnesses, Amedisys Inc., (Nasdaq:AMED), a leading home health, hospice and personal care company, recently launched its second nationwide clinical program this year.
The new initiative will serve home health patients with COPD, or chronic obstructive pulmonary disorder, a group of breathing-related diseases such as emphysema, chronic bronchitis and in some cases asthma. In 2016, Amedisys treated more than 60,000 patients who were diagnosed with COPD, now ranked as the third leading cause of death in the United States.
The COPD program at Amedisys is similar in patient empowerment methodology to a heart failure program Amedisys rolled out in February. At last count, Amedisys had enrolled more than 19,000 patients in its heart failure program. Last year, Amedisys treated some 100,000 patients diagnosed with heart failure.
The new COPD program is likewise interdisciplinary and evidence-based, in this case on guidelines from the Global Initiative for Chronic Obstructive Lung Disease or GOLD standard. Amedisys will deploy its clinicians to educate – and ultimately empower – patients and their families to manage COPD at home.
In the process, patients and caregivers will receive a COPD toolkit and individualized plan of care in conjunction with physician orders. Patients will thereby learn to make critical lifestyle changes intended to help identify and treat symptoms at home, manage medication and therapies which will in turn reduce exacerbations and decrease anxiety. For example, patients will learn to monitor themselves for symptoms and document personal progress on a checklist, and will be educated about breathing techniques, airway clearance and energy conservation.
“The key benefit of our new COPD program is that patients and family members can learn what they can do to help themselves,” says Susan Sender, Senior Vice President and Chief Clinical Officer at Amedisys. “The more they help themselves, the better we can help them.”
The program’s goal is to achieve a higher quality of life -- maintaining wellness and fostering independence – while promoting effective patient-doctor communications, improving functional status, decreasing shortness of breath, preventing avoidable hospital readmissions and lowering costs.
For more information on Amedisys’ COPD program, or to learn more about how home health can help you or your loved one, click here.
About Amedisys
Amedisys, Inc. is a leading healthcare at home Company delivering personalized home health, hospice and personal care. Amedisys is focused on delivering the care that is best for our patients, whether that is home-based personal care; recovery and rehabilitation after an operation or injury; care focused on empowering them to manage a chronic disease; or hospice care at the end of life. More than 2,200 hospitals and 61,900 physicians nationwide have chosen Amedisys as a partner in post-acute care. Founded in 1982, headquartered in Baton Rouge, LA with an executive office in Nashville, TN, Amedisys is a publicly held company. With approximately 16,000 employees, in 421 care centers in 34 states, Amedisys is dedicated to delivering the highest quality of care to the doorsteps of more than 385,000 patients in need every year. For more information about the Company, please visit www.amedisys.com.
Contact:
Kendra Kimmons
Vice President of Marketing & Communications
225-299-3708
[email protected]


MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth
Chinese Brands Are Taking Over Brazil — And It's Just Getting Started
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home
Jefferies Upgrades Starbucks to Hold as China JV Deal Closes and U.S. Business Shows Signs of Recovery
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave
Chinese Cars in Europe: Consumer Trust Is Shifting Fast
OpenAI Addresses Security Vulnerability in macOS App Certification Process
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58%
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 



